FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1873254048> ?p ?o ?g. }

• W1873254048 endingPage "624" @default.
• W1873254048 startingPage "620" @default.
• W1873254048 abstract "Chordoma is a rare type of malignant bone tumor and is known to arise from the remnants of the notochord. Resistance to chemotherapy makes the treatment of chordoma difficult; therefore, new approaches need to be developed to cure this disease. Differentiation therapy, using various differentiating agents, is attracting oncologists as a common therapeutic method to treat other tumors. Based on forcing cells to mature into other lineages, differentiation therapy might be an available method to treat chordomas in addition to conventional therapies.In this study a chordoma cell line, U-CH1, was exposed to several chemotherapeutic agents including vincristine, doxorubicin, cisplatin, etoposide, fludarabine, methotrexate, nilotinib, and imatinib mesylate under appropriate conditions. The first group of U-CH1 cells was exposed to drugs only and the second group of cells was exposed to the simultaneous treatment of 1 μM all-trans retinoic acid (ATRA) and chemotherapeutic agents in differentiation therapy. The efficacy of the differentiation method was assessed by measuring the viability of U-CH1 cells.Vincristine, doxorubicin, etoposide, cisplatin, and fludarabine, each at a concentration of 10 μM, decreased the number of chordoma cells when given alone down to 11%, 0%, 30%, 67%, and 3%, respectively. Etoposide and cisplatin, each at a concentration of 10 μM, reduced the percentage of viable chordoma cells in a more effective way when given with 1 μM ATRA simultaneously, reducing the number of viable cells to 14% and 9%, respectively. On the other hand, imatinib and nilotinib, each at a concentration of 3 μM, as well as 10 μM methotrexate, showed no decrease in the number of cancer cells.The results suggest that chordoma cells may be treated using the differentiation method in a more effective way than when they are treated with chemotherapeutic agents alone. This new approach may be an alternative method to conventional therapies in the treatment of chordoma." @default.
• W1873254048 created "2016-06-24" @default.
• W1873254048 creator A5018122941 @default.
• W1873254048 creator A5029961205 @default.
• W1873254048 creator A5038751207 @default.
• W1873254048 creator A5039241787 @default.
• W1873254048 creator A5039322997 @default.
• W1873254048 creator A5044678753 @default.
• W1873254048 creator A5048130296 @default.
• W1873254048 creator A5087269421 @default.
• W1873254048 date "2011-12-01" @default.
• W1873254048 modified "2023-10-18" @default.
• W1873254048 title "The effects of chemotherapeutic agents on differentiated chordoma cells" @default.
• W1873254048 cites W1970948211 @default.
• W1873254048 cites W1974825648 @default.
• W1873254048 cites W1975372065 @default.
• W1873254048 cites W1981667649 @default.
• W1873254048 cites W2007852760 @default.
• W1873254048 cites W2015896892 @default.
• W1873254048 cites W2026140728 @default.
• W1873254048 cites W2033621114 @default.
• W1873254048 cites W2034328471 @default.
• W1873254048 cites W2039803453 @default.
• W1873254048 cites W2049886568 @default.
• W1873254048 cites W2052628523 @default.
• W1873254048 cites W2054238713 @default.
• W1873254048 cites W2055726227 @default.
• W1873254048 cites W2065106881 @default.
• W1873254048 cites W2069740645 @default.
• W1873254048 cites W2073693387 @default.
• W1873254048 cites W2074126384 @default.
• W1873254048 cites W2099252068 @default.
• W1873254048 cites W2102085111 @default.
• W1873254048 cites W2105796323 @default.
• W1873254048 cites W2118290727 @default.
• W1873254048 cites W2123142428 @default.
• W1873254048 cites W2135121634 @default.
• W1873254048 cites W2143365343 @default.
• W1873254048 cites W2171353922 @default.
• W1873254048 cites W2274550965 @default.
• W1873254048 doi "https://doi.org/10.3171/2011.7.spine10798" @default.
• W1873254048 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21905773" @default.
• W1873254048 hasPublicationYear "2011" @default.
• W1873254048 type Work @default.
• W1873254048 sameAs 1873254048 @default.
• W1873254048 citedByCount "11" @default.
• W1873254048 countsByYear W18732540482013 @default.
• W1873254048 countsByYear W18732540482014 @default.
• W1873254048 countsByYear W18732540482015 @default.
• W1873254048 countsByYear W18732540482016 @default.
• W1873254048 countsByYear W18732540482020 @default.
• W1873254048 countsByYear W18732540482023 @default.
• W1873254048 crossrefType "journal-article" @default.
• W1873254048 hasAuthorship W1873254048A5018122941 @default.
• W1873254048 hasAuthorship W1873254048A5029961205 @default.
• W1873254048 hasAuthorship W1873254048A5038751207 @default.
• W1873254048 hasAuthorship W1873254048A5039241787 @default.
• W1873254048 hasAuthorship W1873254048A5039322997 @default.
• W1873254048 hasAuthorship W1873254048A5044678753 @default.
• W1873254048 hasAuthorship W1873254048A5048130296 @default.
• W1873254048 hasAuthorship W1873254048A5087269421 @default.
• W1873254048 hasConcept C126322002 @default.
• W1873254048 hasConcept C142724271 @default.
• W1873254048 hasConcept C143998085 @default.
• W1873254048 hasConcept C2776694085 @default.
• W1873254048 hasConcept C2776755627 @default.
• W1873254048 hasConcept C2777583451 @default.
• W1873254048 hasConcept C2778119113 @default.
• W1873254048 hasConcept C2778239845 @default.
• W1873254048 hasConcept C2778729363 @default.
• W1873254048 hasConcept C2779429289 @default.
• W1873254048 hasConcept C2781059491 @default.
• W1873254048 hasConcept C2781190729 @default.
• W1873254048 hasConcept C2781303535 @default.
• W1873254048 hasConcept C3019892230 @default.
• W1873254048 hasConcept C502942594 @default.
• W1873254048 hasConcept C71924100 @default.
• W1873254048 hasConcept C98274493 @default.
• W1873254048 hasConceptScore W1873254048C126322002 @default.
• W1873254048 hasConceptScore W1873254048C142724271 @default.
• W1873254048 hasConceptScore W1873254048C143998085 @default.
• W1873254048 hasConceptScore W1873254048C2776694085 @default.
• W1873254048 hasConceptScore W1873254048C2776755627 @default.
• W1873254048 hasConceptScore W1873254048C2777583451 @default.
• W1873254048 hasConceptScore W1873254048C2778119113 @default.
• W1873254048 hasConceptScore W1873254048C2778239845 @default.
• W1873254048 hasConceptScore W1873254048C2778729363 @default.
• W1873254048 hasConceptScore W1873254048C2779429289 @default.
• W1873254048 hasConceptScore W1873254048C2781059491 @default.
• W1873254048 hasConceptScore W1873254048C2781190729 @default.
• W1873254048 hasConceptScore W1873254048C2781303535 @default.
• W1873254048 hasConceptScore W1873254048C3019892230 @default.
• W1873254048 hasConceptScore W1873254048C502942594 @default.
• W1873254048 hasConceptScore W1873254048C71924100 @default.
• W1873254048 hasConceptScore W1873254048C98274493 @default.
• W1873254048 hasIssue "6" @default.
• W1873254048 hasLocation W18732540481 @default.
• W1873254048 hasLocation W18732540482 @default.

• next